- CRISPR and Genetic Engineering
- DNA Repair Mechanisms
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA and protein synthesis mechanisms
- PARP inhibition in cancer therapy
- Fibroblast Growth Factor Research
- Bladder and Urothelial Cancer Treatments
- Epigenetics and DNA Methylation
Roche (Switzerland)
2021-2022
To study associations across tumor types between genome-wide loss of heterozygosity (gLOH) and alterations in homologous recombination repair (HRR)-associated genes beyond BRCA1 BRCA2.
<div>AbstractPurpose:<p>To study associations across tumor types between genome-wide loss of heterozygosity (gLOH) and alterations in homologous recombination repair (HRR)-associated genes beyond <i>BRCA1</i> <i>BRCA2</i>.</p>Experimental Design:<p>Genomic profiling using a targeted next-generation sequencing assay examining 324–465 (FoundationOne, FoundationOne Heme, CDx; Foundation Medicine, Inc.) was performed cohort 160,790 samples...
Supplementary Data from Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
<div>AbstractPurpose:<p>To study associations across tumor types between genome-wide loss of heterozygosity (gLOH) and alterations in homologous recombination repair (HRR)-associated genes beyond <i>BRCA1</i> <i>BRCA2</i>.</p>Experimental Design:<p>Genomic profiling using a targeted next-generation sequencing assay examining 324–465 (FoundationOne, FoundationOne Heme, CDx; Foundation Medicine, Inc.) was performed cohort 160,790 samples...
Supplementary Data from Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score